Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Sanofi save search
The Rockefeller Foundation Commits USD 100 Million to Test and Scale Climate and Health Solutions Globally
Published: 2023-12-02 (Crawled : 12:20) - prnewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
test health solutions 100
41 Funders, Partners Endorse New Guiding Principles for Financing Climate and Health Solutions to Protect Health
Published: 2023-12-02 (Crawled : 12:20) - prnewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
health solutions
Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd., Amgen Inc., AstraZeneca Plc, Athenex Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $8.5 5.21% 100
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
AZN | $64.79 0.31% 0.03% 3.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $125.0 -2.72% 8.8% 3.4K
|
Health Technology
| Email alert
Add to watchlist
AMGN G | $272.45 1.04% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
companies astrazeneca cancer therapeutics market
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 19:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100
|
Health Technology
| Email alert
Add to watchlist
BHC | $7.36 3.08% 0.0% 1.8M
|
Health Technology
| Email alert
Add to watchlist
BIIB | $234.64 0.24% 0.26% 570K
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
BCLI | $0.26 -6.81% -7.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
VTRS | $9.37 2.07% 1.92% 6.4M
|
Health Technology
| Email alert
Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
| Email alert
Add to watchlist
disease companies health therapeutics market
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster S...
Published: 2023-12-01 (Crawled : 14:30) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status
Published: 2023-12-01 (Crawled : 13:30) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
Published: 2023-12-01 (Crawled : 06:00) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
INCY | $54.02 -0.59% 1.07% 1.9M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
ibi351 lung congress update cancer asia
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $9.71 -1.12% 0.0% 6.6M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR | DelveInsight
Published: 2023-11-29 (Crawled : 22:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
IMMP | $1.99 1.01% 83K
|
Health Technology
|
| O: 6.45%
H: 1.52%
C: 0.51%
breast cancer market
Deals, Dupixent and GLP-1 drug shortages
Published: 2023-11-29 (Crawled : 15:30) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -0.15%
H: 0.07%
C: -0.66%
drug dupixent
Metastatic Non-small Cell Lung Cancer Market Forecast Analysis and with Focus on its Immune/Molecular Biomarker Types: PD-L1, EGFR, KRAS, ALK, BRAF, MET, ROS-1, HER2, RET fusion, and NTRK1/2/3 Gene fusion | DelveInsight
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
LLY 2 d | $584.04 -1.18% 0.34% 3.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -0.15%
H: 0.07%
C: -0.66%
BPMC | $72.05 3.46% 0.0% 820K
|
Health Technology
|
| O: 0.5%
H: 1.86%
C: -0.33%
lung biomarker cancer cell market
FDA Decisions: First Treatment for Desmoid Tumors and a Dry Eye Rejection for Aldeyra
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
PRGO P | $30.9 1.44% 0.0% 1.3M
|
Health Technology
|
| O: 0.78%
H: 0.81%
C: -1.71%
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
ABT | $104.88 0.57% -0.01% 4.7M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
fda tumors treatment eye
Vaxcyte Appoints Jacks Lee to Board of Directors
Published: 2023-11-28 (Crawled : 14:00) - globenewswire.com
PPRUF | $426.544 -2.5% 44.35% 1.5K
|
Consumer Non-Durables
|
| O: -1.83%
H: 1.83%
C: -2.33%
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
PCVX S | $53.81 3.94% 0.0% 600K
|
Health Technology
|
| O: -1.82%
H: 1.91%
C: 1.75%
STRO | $2.75 5.36% 5.26% 1M
|
Health Technology
|
| O: 6.14%
H: 1.24%
C: -5.79%
GTHX | $2.0 6.38% 5.53% 1.1M
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth - Technavio
Published: 2023-11-27 (Crawled : 22:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
VTRS | $9.37 2.07% 1.92% 6.4M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.93%
TAK | $14.17 0.14% 0.0% 830K
|
Health Technology
|
| O: -0.07%
H: 0.28%
C: 0.21%
ABT | $104.88 0.57% -0.01% 4.7M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
VNDA | $3.9 4.84% 4.86% 890K
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -3.01%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
america therapeutics growth market
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
dupixent positive copd results sanofi
Innate Pharma to Host Virtual KOL Event on Lacutamab
Published: 2023-11-27 (Crawled : 11:00) - biospace.com/
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
IPHA | $2.44 1.67% -2.13% 12K
|
Health Technology
|
| O: 2.07%
H: 1.21%
C: 1.21%
pharma
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K
|
Health Technology
|
| O: -0.03%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K
|
Health Technology
|
| O: -0.03%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Biotech Breakthrough
Published: 2023-11-26 (Crawled : 00:00) - spacfeed.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
biotech
Rabies Vaccine Market to Reach $ 1903.17 million by 2032, exhibiting a CAGR of 4.7% from 2023 to 2032: Allied Market Research
Published: 2023-11-25 (Crawled : 08:20) - prnewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
ELAN | $12.4 5.26% 0.08% 6.6M
|
Process Industries
| Email alert
Add to watchlist
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100
|
Health Technology
| Email alert
Add to watchlist
ZTS | $179.13 1.39% 0.49% 1.4M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | $12.36 0.08% -26.03% 1K
|
Communications
| Email alert
Add to watchlist
vaccine reach research market
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K
|
Finance
BKKT 4 | $1.88 25.33% 14.89% 4.8M
|
MGLD | $1.03 7.77% 14K
|
Manufacturing
CZOO | $0.4316 -6.52% 6.7% 65K
|
SATX | $0.4226 -1.72% 6.48% 29K
|
n/a
CCJ | $45.4 -1.13% 4.6% 3.9M
|
Non-Energy Minerals
AUMN | $0.562 0.34% 4.5% 360K
|
Non-Energy Minerals
JBL | $116.91 1.38% 4.3% 2M
|
Electronic Technology
SAIC 4 | $119.92 2.14% 4.24% 460K
|
Technology Services
CULP 4 | $5.06 -0.59% 3.95% 29K
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.